Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients

Colorectal Cancer Clinical Trial

— CIFRA  

Official title:

Cetuximab, Irinotecan and Fluorouracile in fiRst-line Treatment of Immunologically-selected Advanced Colorectal Cancer Patients: the CIFRA Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03874026
• Other study ID #: 60/18
• Status: Recruiting
• Phase: Phase 2
• Start date: September 5, 2019
• Est. completion date: May 2024

Study information

• Verified date: October 2023
• Source: National Cancer Institute, Naples
• Contact: Alessandro Ottaiano, MD
• Phone: +39 081 5903510
• Email: ale.otto[@]libero.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients' selection thorough the identification of predictive factors still represent a challenge in metastatic colorectal cancer (mCRC). Cetuximab (Erbitux®), a chimeric monoclonal antibody binding to the Epidermal Growth Factor Receptor (EGFR), belongs to the Immunoglobulins (Ig) grade 1 subclass able to elicit both in vitro and in vivo the Antibody-Dependent Cell-mediated Cytotoxicity (ADCC). ADCC is the cytotoxic killing of antibody-coated target cells by immunologic effectors. The effector cells express a receptor for the Fc portion of these antibodies (FcγR); genetic polymorphisms of FcγR modify the binding affinity with the Fc of IgG1 (Immunoglobulins Gamma subclass 1). Interestingly, the high-affinity FcγRIIIa (FcγR type IIIa) V/V is associated with increased ADCC in vitro and in vivo. Thus, ADCC could partially account for cetuximab activity. CIFRA is a single arm, open-label, phase II study assessing the activity of cetuximab in combination with irinotecan and fluorouracile in FcγRIIIa V/V patients with KRAS (Kirsten RAt Sarcoma), NRAS (Neuroblastoma Rat Sarcoma), BRAF (B-Rapidly Accelerated Fibrosarcoma) wild type mCRC. The study is designed with a two-stage Simon model based on a hypothetical higher response rate (+10%) of FcγRIIIa V/V patients as compared to previous trials (about 60%) assuming ADCC as one of the mechanisms of cetuximab action. The test power is 95%, the alpha value of the I-type error is 5%. With these assumptions the sample for passing the first stage is 14 patients with >6 responses and the final sample is 34 patients with >18 responses to draw positive conclusions. Secondary objectives include toxicity, responses' duration, progression-free and overall survival. Furthermore, an associated translational study will assess the patients' cetuximab-mediated ADCC and characterize the tumor microenvironment. The CIFRA study will determine whether ADCC contributes to cetuximab activity in mCRC patients selected on an innovative immunological screening. Data from the translational study will support results'interpretation as well as provide new insights in host-tumor interactions and cetuximab activity.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 34
• Est. completion date: May 2024
• Est. primary completion date: May 19, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Cytological or histological diagnosis of colorectal adenocarcinoma;
• KRAS, NRAS, BRAF wild-type;
• Fc?RIIIaV/V genotype;
• stage IV;
• age <75 years;
• at least 1 measurable lesion;
• ECOG (Eastern Cooperative Oncology Group) Performance Status 0 or 1;
• life expectancy> 3 months;
• negative pregnancy test for all potentially childbearing women;
• written informed consent.

Exclusion Criteria:

• previous systemic anti-tumor treatment (allowed treatment with capecitabine or fluorouracil and radiotherapy in the neoadjuvant setting of rectal tumors with therapy terminated at least 6 months before);
• presence of primary non-treated stenosing colorectal neoplasm;
• neutrophils <2000/mm³ or platelets <100.000/mm³ or hemoglobin <9 g/dl;
• serum creatinine level> 1.5 times the maximum normal value;
• GOT (glutamic oxaloacetic transaminase) and/or GPT (glutamic pyruvic transaminase) >5 times the maximum normal value and/or bilirubin level >3 times the maximum normal value;
• previous malignant neoplasms (excluding basal or spinocellular cutaneous carcinoma or in situ carcinoma of the uterine cervix);
• active or uncontrolled infections;
• other concomitant uncontrolled diseases or conditions contraindicating the study - drugs at clinician evaluation;
• presence of brain metastases;
• refusal or inability to provide informed consent;
• impossibility to guarantee follow-up.

Related Conditions & MeSH terms

• ADCC
• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Drug:
• Folfiri/Cetuximab
Cetuximab 400 mg/mq intravenously (iv) with "load" dose of 400 mg/mq at the first cycle followed by 250 mg/mq iv weekly by iv infusion in 90 minutes. The administration of irinotecan will precede that of cetuximab and will consist on a dose of 180 mg/mq iv in 60 minutes every two weeks and it will be followed by fluorouracil (5-FU) at a dose of 400 mg/mq in slow iv bolus at half of lederfolin 200 mg/mq 2-hours infusion. At the end of the infusion of lederfolin an elastomeric pump loaded with 5-FU 2400 mg/mq in continuous 46 hours iv infusion will be applied. Only at the first administration of CT ("load" dose of cetuximab), irinotecan will not be administered.

Locations

Country	Name	City	State
Italy	Istituto Nazionale dei Tumori,	Napoli

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute, Naples

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Percentage of antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro through the evaluation of tumor cell lysis after co-incubation of tumor cells, cetuximab and patient-derived lymphocytes.	To study cetuximab-mediated ADCC, peripheral blood mononuclear cells from patients will be isolated, and added in the presence of cetuximab to colorectal cancer cells. The specific cytolysis will be evaluated by sulforhodamine B (SRB) assay and the percentage of lysis will be calculated using the following formula: Cytotoxicity (%) = [1 - (mean test optical density/mean optical density target)] × 100.	Before treatment start
Other	Type of cells infiltrating the tumor microenvironment.	The primary tissues, and metastases when available, will be characterized for the presence of tumor-infiltrating M1 and M2 macrophages and tumor-infiltrating lymphocytes by immunohistochemistry through the expression of CD163 (ab182422, Abcam), TGF-ß (Tumor Growth Factor beta) (ab92486, Abcam), Arginase-1 (GTX113131, Genetex), Osteopontin (ab218237, Abcam], and PD-L1 (Programmed Death-Ligand 1) (E1L3N®, XP®). M1 infiltrating macrophages will be detected through the following antibodies: CD86 (Cluster of Differentiation 86) (ab53004, Abcam), iNOS (inducible Nitric Oxide Synthase) (ab115819, Abcam), IFN-? (InterFeroN-gamma) (ab218426, Abcam), TNF (Tumor Necrosis Factor) (ab1793, Abcam). Natural Killer (NK) and Cytotoxic T Lymphocytes (CTL) will be characterized as follows: NKP46+ (Clone 195314, R&D system), granzyme B (ab134933, Abcam), Foxp3+ (ab20034, Abcam). Results will be expressed for any type of cells in percentages (numerical proportions of stained cells).	Before treatment start
Primary	Activity	Activity assessed by RECIST criteria version 1.1	1 year
Secondary	Response duration	Time elapsed from date of response to progression occurrence.	1 year
Secondary	Progression-free survival (PFS)	PFS will be determined from the date of treatment start until progression.	Through study completion, an average of 1 year
Secondary	Overall survival (OS)	OS will be measured from treatment start until death from any cause.	Through study completion, an average of 2 years
Secondary	Toxic effects	Toxic effects assessed by CTCAE of the National Cancer Institute, version 4.0, June 14, 2010	At the end of Cycle 1 (each cycle is 14 days)